IV
Live price temporarily unavailable.
Price history
Invivyd (IVVD) is a Health Care company in the Russell 2000. Latest news and coverage below.
Invivyd revenue & net income history (FY2021–FY2025)
RevenueNet income
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $25.4M | $53.4M |
| Growth (year over year) | — | — | — | — | +110.5% |
| Operating income | −$226.9M | −$248.0M | −$212.8M | −$176.9M | −$55.6M |
| Operating margin | — | — | — | −696.8% | −104.0% |
| Net income | −$226.8M | −$241.3M | −$198.6M | −$169.9M | −$52.5M |
| Net margin | — | — | — | −669.4% | −98.2% |
| EPS (diluted) | −$5.32 | −$2.23 | −$1.81 | −$1.43 | −$0.30 |
| Balance sheet | |||||
| Cash and equivalents | $542.2M | $92.1M | $200.6M | $69.3M | $226.7M |
| Total assets | $620.1M | $383.2M | $229.2M | $129.5M | $276.9M |
| Total liabilities | $62.1M | $27.2M | $51.7M | $62.0M | $35.3M |
| Shareholders' equity | $558.0M | $356.0M | $177.5M | $67.5M | $241.5M |
| Cash flow | |||||
| Operating cash flow | −$184.7M | −$220.0M | −$173.2M | −$170.5M | −$58.1M |
| Capital expenditure | $84.0K | $1.71M | $615.0K | $140.0K | $155.0K |
| Free cash flow | −$184.8M | −$221.7M | −$173.8M | −$170.6M | −$58.3M |
| Share buybacks | $0 | $4.00K | $1.00K | $0 | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.30M | — | $11.3M | $11.8M | $13.1M | $17.2M | $13.7M | $14.3M |
| Growth (year over year) | — | — | — | +420.6% | +41.2% | — | +21.6% | +21.2% |
| Operating income | −$62.3M | — | −$16.9M | −$15.1M | −$11.0M | −$12.6M | −$43.1M | −$45.8M |
| Operating margin | −670.0% | — | −149.7% | −127.8% | −84.0% | −73.0% | −313.9% | −320.8% |
| Net income | −$60.7M | — | −$16.3M | −$14.7M | −$10.5M | −$11.1M | −$41.4M | −$44.4M |
| Net margin | −653.1% | — | −144.1% | −124.4% | −79.7% | −64.3% | −301.2% | −310.8% |
| EPS (diluted) | −$0.51 | — | −$0.14 | −$0.12 | −$0.06 | $0.02 | −$0.13 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $106.9M | $69.3M | $48.1M | $34.9M | $85.0M | $226.7M | $184.2M | $160.1M |
| Total assets | $161.9M | $129.5M | $103.7M | $89.1M | $139.2M | $276.9M | $241.7M | $218.9M |
| Total liabilities | $78.8M | $62.0M | $49.6M | $46.3M | $46.1M | $35.3M | $38.7M | $37.8M |
| Shareholders' equity | $83.2M | $67.5M | $54.1M | $42.8M | $93.1M | $241.5M | $203.1M | $181.1M |
| Cash flow | ||||||||
| Operating cash flow | −$41.1M | — | −$21.1M | −$13.3M | −$8.25M | −$15.5M | −$41.7M | −$43.0M |
| Capital expenditure | $5.00K | — | $144.0K | $11.0K | $0 | $0 | $726.0K | $510.0K |
| Free cash flow | −$41.1M | — | −$21.3M | −$13.3M | −$8.25M | −$15.5M | −$42.4M | −$43.5M |
| Share buybacks | $0 | — | — | — | — | — | — | — |
From Invivyd's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Invivyd
- Headquarters
- New Haven, Connecticut From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with IVVD
- IRWD Ironwood Pharma Inc Class a
- ISPC iSpecimen
- ITGR Integer Holdings Corp
- IVA Inventiva
- JAGX Jaguar Health
- JANX Janux Therapeutics Inc
- JAZZ Jazz Pharmaceuticals
- JBIO Jade Biosciences Inc